Clinical Trials Browser

Phase 2 × Carcinoma, Endometrioid × Clear all

NCT02834013 2026-06-03

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Phase 2 Active not recruiting

CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcoma

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

NCT03660826 2026-06-02

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Phase 2 Active not recruiting

288 enrolled 21 charts

Carcinosarcoma, Carcinoma, Endometrioid

NCT05112601 2026-04-21

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Phase 2 Recruiting

Endometrial Neoplasms, Carcinoma, Endometrioid

NCT04065269 2026-02-20

ATARI

Phase 2 Active not recruiting

GynecologicSarcoma

Carcinosarcoma, Uterine Cervical Neoplasms, Endometrial Neoplasms, Carcinoma, Endometrioid

NCT06463028 2025-12-24

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

Phase 2 Recruiting

Genital Diseases, Hereditary Sensory and Autonomic Neuropathies, Endometrial Neoplasms, Carcinoma, Endometrioid

NCT01935934 2025-10-01

Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

Phase 2 Completed

102 enrolled 14 charts

Carcinoma, Endometrioid

NCT05080556 2024-04-12

ACTOv

Phase 2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Carcinoma, Endometrioid

NCT03824704 2023-06-12

A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)

Phase 2 Terminated

1 enrolled 7 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Carcinoma, Endometrioid

NCT02728258 2022-02-15

Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Phase 2 Completed

11 enrolled 12 charts

Carcinoma, Endometrioid

NCT02093598 2020-11-27

POEM

Phase 2 Completed

Carcinoma, Endometrioid